Health · 2 views
Safer stroke prevention strategies are needed for patients with atrial fibrillation after intracranial hemorrhage
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session at ESC Congress…
Story Brief
Atrial fibrillation (AF) is the most common form of irregular heart rhythm and a leading cause of ischemic stroke, where a blood clot cuts off the blood supply to part of the brain. Oral anticoagulants such as edoxaban are highly effective at preventing ischemic stroke in patients with AF, but they come with concerns over bleeding risk. These concerns are amplified in patients with AF who have had a prior intracranial hemorrhage , which includes bleeding within or around the brain.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Digital strategy helps patients with heart failure to receive proven medicationContinue reading
- After TAVI, anticoagulants outperform antiplatelet agents at preventing clotsContinue reading
- Public confidence in one's own health care provider remains highContinue reading
- High fertility costs push Americans abroad for IVF treatmentContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow